New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

VIZIMPRO® (dacomitinib) tablets, for oral use

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email to discuss.

Facts of Vizimpro (dacomitinib)

VIZIMPRO® (dacomitinib) tablets, for oral use
Brand Name: Vizimpro
Generic Name: dacomitinib
Initial U.S. Approval: 2018
Strength: Tablets: 15 mg, 30 mg, and 45 mg.
Manufacturer: Pfizer, Inc

South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Vizimpro (dacomitinib) ” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Vizimpro (dacomitinib) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.



Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:

Query Form


What Vizimpro is?

VIZIMPRO is an oral, once-daily, irreversible pan-human epidermal growth factor receptor kinase inhibitor. VIZIMPRO is approved in the EU for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.

VIZIMPRO is also approved in the United States for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. Additionally, VIZIMPRO is approved in Japan for EGFR gene mutation-positive, inoperable or recurrent NSCLC, and in Canada for the first-line treatment of adult patients with unresectable locally advanced or metastatic NSCLC with confirmed EGFR exon 19 deletion or exon 21 L858R substitution mutations. The applications in the US and Japan were reviewed and approved under the Priority Review program.

What dacomitinib is?

Dacomitinib (trade name Vizimpro) is a drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR. Dacomitinib has advanced to several Phase III clinical trials.[when?] The January 2014 results of the first trials were disappointing, with a failure to meet the study goals. Additional Phase III trials are ongoing[when?].

In 2017, results of a trial comparing dacomitinib to gefitinib for NSCLC (driven by mutated EGFR) were announced. Dacomitinib was approved in the United States in 2018, in Japan in 2019 and in the European Union (EU) authorized by the European Medicines Agency (EMA) in 2019 for the treatment of non-small cell lung cancer with EGFR gene mutation.


Related Products